|
WO2020141535A1
|
|
An a3 adenosine receptor ligand for use for achieving a fat loss effect
|
|
IL254535D0
|
|
A3 adenosine receptor ligand for managing cytokine release syndrome
|
|
IL242723D0
|
|
An a3 adenosine receptor ligand for use in treating ectopic fat accumulation
|
|
IL233740D0
|
|
Treatment of liver conditions
|
|
JP2014144969A
|
|
Method for inducing hepatocyte proliferation and uses thereof
|
|
CA2880753A1
|
|
A3 adenosine receptor ligands for use in treatment of a sexual dysfunction
|
|
US2015018299A1
|
|
Treatment of liver conditions
|
|
IL221469D0
|
|
A3ar agonists for the treatment of uveitis
|
|
AU2010250759A1
|
|
A3 adenosine receptor agonists for the reduction of intraocular pressure
|
|
IL200753D0
|
|
Pharmaceutical composition comprising ib-meca for the treatment of psoriasis
|
|
IL200711D0
|
|
Process for the synthesis of ib-meca
|
|
CN101820883A
|
|
Uses of A3AR agonist in preparing medicine for inducing hepatocyte proliferation
|
|
IL191269D0
|
|
Use of a3 adenosine receptor agonist in the preparation of a pharmaceutical composition for osteoarthritis treatment
|
|
HUE034474T2
|
|
Process for the synthesis of ib-meca
|
|
WO2008056361A1
|
|
A biological marker for psoriasis
|
|
IL184620D0
|
|
Composition for the treatment of inflammation
|
|
IL182986D0
|
|
Methods for determining effectiveness of an anti-inflammatory treatment and for selecting a subject to receive such treatment
|
|
IL182988D0
|
|
Therapeutic treatment of accelerated bone resorption
|
|
IL182987D0
|
|
Treatment of inflammation
|
|
WO2007063538A1
|
|
Use of a3 adenosine receptor agonist in osteoarthritis treatment
|
